As a class II histone deacetylase (HDAC) inhibitor vorinostat in combination with the vascular endothelial growth factor (VEGF) inhibitor bevacizumab has been relatively well tolerated and clinical efficacy in the treatment of patients with metastatic ccRCC [51]. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.